Answers are grounded in this paper and cite their sources.
Background People with HIV (PWH) on antiretroviral therapy (ART) exhibit persistent immune activation, chronic inflammation, and accelerated comorbidities despite viral suppression. Cannabinoid-based medicines have anti-inflammatory properties, suggesting their potential to reduce inflammation in PWH, yet their cellular and transcriptomic effects on immune cells remain poorly characterized. Herein, the changes in gene expression signature associated with immune cells and inflammatory pathways in PWH receiving oral cannabinoids combined with ART were assessed. Methods PBMCs from six ART-treated PWH enrolled in the Canadian HIV Trials Network pilot study CTN PT028 were longitudinally analyzed by single-cell RNA sequencing before and after 12 weeks of treatment. Participants were treated with either cannabidiol (CBD) alone or combined cannabidiol and Δ9-tetrahydrocannabinol (THC). Differential gene expression and pathway enrichment analyses were performed across immune cell subsets to characterize cannabinoid-induced transcriptional reprogramming. Results Across 81,868 single-cell transcriptomes, 13 immune subsets were identified, with the greatest transcriptional shifts observed in CD14 + classical monocytes and CD8 + T-cells following oral cannabinoid treatment. Combined THC: CBD treatment induced broader gene perturbations than CBD alone. Cannabinoid exposure altered expression of endocannabinoidome (eCBome)-associated genes, including TRPV2 , PTGS2 , PTGES , and CNR2 , highlighting extensive remodeling of endocannabinoids and lipid-signaling pathways. Across myeloid and lymphoid populations, a conserved transcriptional signature emerged characterized by attenuation of interferon signaling, reduced expression of antiviral restriction factors and interferon-stimulated genes, and diminished innate sensing and antigen-presentation pathways. Concurrently, cannabinoids induced extensive reorganization of inflammatory and activation-associated networks, including NF-κB-, TGF-β-, and stress-response pathways. T-cell populations displayed coordinated remodeling of RNA processing, metabolic, apoptotic, and cell-cycle programs, while both treatments induced circadian-associated transcriptional regulators, suggesting broad effects on immune homeostasis. Finally, oral cannabinoid treatment also modulated host pathways linked to HIV transcriptional control and viral restriction. Conclusions Oral cannabinoids induce a multidimensional, cell-type-specific immune reprogramming characterized by the modulation of inflammatory, antiviral, metabolic, circadian, and immunoregulatory pathways in ART-treated PWH. These findings provide mechanistic insight into the immunomodulatory effects of cannabinoids and support their potential as adjunctive approaches to reduce chronic immune activation and inflammation in treated HIV infection. Trial registration https://clinicaltrials.gov/study/NCT03550352?cond=HIV&viewType=Card&term=Cannabinoids&rank=1 , identifier NCT0355035.
No takes yet. Share an insight, caveat, or question.
Yero et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: